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ABSTRAK
Reaktivasi virus hepatitis B (HBV) setelah dilakukan kemoterapi dan terapi imunosupresi merupakan 
akibat serius yang menimbulkan mortalitas dan morbiditas yang berkaitan dengan penyakit hati. Mekanisme 
reaktivasi HBV masih belum jelas, tetapi para ahli meyakini bahwa mekanismenya melalui penekanan respons 
imum sehingga dapat meningkatkan beban virus (viral load). Hingga kini, belum ada kriteria diagnostik yang 
disepakati, namun reaktivasi HBV dapat dipastikan oleh adanya peningkatan kadar HBV-DNA dalam serum. 
Berbagai konsensus telah membahas hal ini yang meliputi pembahasan tentang jenis dan lamanya terapi analog 
nukleosida sebagaimana telah diketahui tidak semua pasien dengan hepatitis B kronik akan mengalami reaktivasi. 
Saat ini, kesadaran akan reaktivasi virus hepatitis B yang samar kini semakin meningkat, khususnya di daerah 
endemis virus hepatitis B, termasuk Indonesia yang merupakan bagian dari wilayah Asia Pasifik. Terapi antivirus 
profilaksis (preempative antiviral therapy) merupakan pendekatan terbaik untuk mencegah reaktivasi HBV. 
Kata kunci: reaktivasi virus Hepatitis B, kemoterapi, imunosupresif.
ABSTRACT
Hepatitis B virus (HBV) reactivation after chemotherapy or immunosuppressive therapy is a serious cause 
of liver-related morbidity and mortality. The mechanism of HBV reactivation is still unclear, but it is believed 
due to the suppression of immune response hence increasing the viral load. No uniform diagnostic criteria 
are available, HBV reactivation can be confirmed by an increase in serum HBV-DNA level. There are many 
consensus regarding this issue, including the type and duration of nucleoside analogue therapy which need to 
be understood as not all chronic hepatitis B patients will lead to HBV reactivation. Recently, there has been an 
increased awareness of reactivation of occult hepatitis B virus, especially in hepatitis B virus endemic area, 
including Indonesia as part of Asia Pacific region. Preempative antiviral therapy was the best approach to 
prevent the HBV reactivation.
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INTRODUCTION
Hepatitis B virus (HBV) reactivation can 
occur in chronic hepatitis B patient. This issue 
should be put into account due to serious 
condition that can lead to fulminant hepatitis, 
liver failure, and eventually death.1
The incidence is unclear, but this condition 
can be predicted and preventable through 
evaluation of risk factors, including patient 
with malignancy who need chemotherapy and 
imunosuppresant agent.1
Complete HBV serology profile should be 
screened in patient who will undergo cytotoxic 
chemotherapy and immunosuppressive therapy. 
It has been known that preempative antiviral 
therapy is more effective than treatment of HBV 
reactivation.1
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HEPATITIS B VIRUS
Hepatitis B virus is a double-stranded DNA 
virus in Hepadnaviridae family. HBV virion are 
double-shelled particles, 40 to 42 nm in diameter, 
with an outer lipoprotein envelope that contains 
three related envelope glycoproteins (surface 
antigens). The core contains the viral genome 
and a polymerase for the viral DNA synthesis in 
infected cells.1
PATHOGENESIS OF HEPATITIS B
Host immune responses to viral antigens on 
infected hepatocytes are the main mechanism 
of hepatocellular injury.2 These responses 
involve both major-histocompatibility-complex 
(MHC) class II–restricted, CD4+ helper T cells 
and MHC class I–restricted, CD8+ cytotoxic T 
lymphocytes. Recognition reaction of antigen 
and antigen presenting cell (APC) can lead to 
either direct lysis of the infected hepatocyte or 
the release of interferon-γ (IFN-γ) and TNF-α, 
which can down-regulate viral replication in 
surrounding hepatocytes without direct cell 
killing.3
Natural histroy of chronic hepatitis B 
infection depends on the age at the time of 
infection and the immune response between 
host immunity and viral replication. Patient who 
failed to recover from acute infection will lead 
to chronic infection through 4 phase: immune 
tolerance, immune clearance, non-replicative, 
and reactivation phase.1
HBV reactivation is related to serologic profile 
and intensity of immunosuppressive agent.7 The 
pathogenesis of HBV reactivation is still unclear, 
for those receiving high dose or long term of 
corticosteroids, it maybe due to a glucocorticoid 
responsive element in the HBV genome that 
stimulates viral replication and transcriptional 
activity.15 The use of chemotherapy will markedly 
suppress the immune response hence increasing 
the viral load.8
EPIDEMIOLOGY
Approximately 2 billion people worldwide 
have been infected with HBV during their 
lifetime, with >350 million remaining chronically 
infected, leading to terminal liver disease or 
hepatocellular carcinoma which accounts for 1 
million of death annualy. Approximately 45% of 
population are in HBV endemic area.5
HEPATITIS B VIRUS REACTIVATION
HBV reactivation is a liver necroinflammation 
in inactive carrier or resulation phase 
patient. Clinical symptoms are variable from 
asymptomatic to liver decompensated and 
death.6 HBV reactivation is related to serologic 
profile and intensity of immunosuppressive 
agent.7 The pathogenesis of HBV reactivation 
is still unclear. The use of chemotherapy and 
highly immunosuppressive agent will markedly 
suppress the immune response hence increasing 
the viral load and if the agent was ceased, there 
will be a fast recovery of immune response and 
massive cytolitic of infected hepatocytes.8
HBV Reactivation Related to Chemotherapy 
Agent 
Currently, there are many reports about HBV 
reactivation related to chemotherapy and the risk 
of reactivation is increasing.9
Patient with HBsAg (+). Lymphoma patients 
who are HbsAg (+) are noted to have a higher 
risk of HBV reactivation after chemotherapy, 
this may be related to the relatively more 
immunosuppressive drugs used for lymphoma 
and also possibly the intrinsic immunosuppressive 
effect of lymphoma.10 A prospective study found 
that ≥60% HBV reactivation occurs in HBsAg (+) 
patient receiving cytotoxic therapy.11 Intrahepatic 
covalently closed circular DNA (cccDNA) is 
Figure 1. Cellular immune responses to hepatitis B virus3
Figure 2. Natural history of chronic hepatitis B4
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the key of viral replication and can be used 
for predicting HBV reactivation in HBsAg (+) 
patient receiving chemotherapy.12
Patient with HBsAg (-). Patient with HBsAg 
(-), anti-HBc (+) and undetectable HBV-DNA, 
ALT and HBV-DNA must be evaluated and 
treated with nucleoside analog despite of ALT 
level.13 HBV reactivation in patient with HBsAg 
(-) but anti-HBc & anti-HBs (+) and in patient 
with occult anti-HBc is an uncommon condition 
therefore it is not recommended for routine 
antiviral prophylaxis. This patient should be 
evaluated and treated if HBV-DNA is detectable.6 
A separate study in Taiwan by Chen et al. has 
shown that 6% of their HbsAg (-) patients with 
B-cell lymphoma had occult HBV infection.13 
In a cohort study by Hui et al. of HBsAg (-) 
hematopoietic stem cell transplant donors in 
Hong Kong, the prevalence of occult HBV 
infection was 15.3%.14
HBV Reactivation Related to Immuno-
suppressive Agent
Corticosteroid. HBV replication increases in 
the presence of corticosteroids. The peak rise in 
aminotransferases typically occurs 4-6 weeks 
after withdrawal. The mechanisms are unclear, 
maybe due to a glucocorticoid responsive 
element in the HBV genome that stimulates 
viral replication and transcriptional activity.15 
Study by Cheng et al. found that a steroid-free 
Table 1. Chemotherapy agent related to HBV reactivation1
Class Agents associated with HBV reactivation Potential hepatotoxicity
Alkylators Cyclophosphamide VOD, hepatocellular injury
Ifosfamide Hepatocellular injury, cholestasis
Chlorambucil Hepatocellular injury
Carboplatin, cisplatin Hepatocellular injury, cholestasis, steatosis, peliosis
Antimetabolites Cytarabine VOD, hepatocellular injury
Fluorouraril Hepatocellular injury
Gemcitabine Hepatocellular injury, cholestasis
Mercaptopurine Hepatocellular injury, cholestasis
Methotrexate Hepatocellular injury, steatosis, fibrosis, hepatic 
neoplasm
Thioguanine VOD, hepatocellular injury, NRH, peliosis
Antitumor antibiotics Anthracyclines Hepatocellular injury, VOD
Bleomycin Steatosis
Mitomycin C VOD, steatosis
Actinomycin D VOD, steatosis
Corticosteroides Prednisone/Dexamethasone, etc Hepatomegaly (rare association)
Immunotherapy Rituximab (anti-CD20) Hepatocellular injury
Alemtuzumab (anti-CD52) Hepatocellular injury
Infliximab (anti-TNF) Hepatocellular injury, steatosis
Plant Alkaloids Vincristine VOD, hepatocellular injury
Vinblastine Hepatocellular injury





Imatinib mesylate Hepatocellular injury, cholestasis
Interferon alpha Hepatocellular injury
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chemotherapy regimen reduced the risk of HBV 
reactivation in patients with lymphoma.16
Monoclonal Antibody. Lymphoid malignancies 
and immunologic conditions often includes the 
use of monoclonal antibodies, such as rituximab 
(anti-CD20) and alemtuzumab (anti-CD52) 
which are highly immunosuppressive.1 Rituximab 
plus CHOP chemotherapy (cyclophosphamide, 
doxorubicin, vincristine, and prednisolone) is 
now a standard treatment of diffuse large B-cell 
lymphoma (DLBCL).15 Before preemptive anti-
HBV therapy is widely used, treatment of HBsAg 
(+) lymphoma with CHOP chemotherapy alone 
is associated with an approximately 50% risk of 
HBV reactivation, the risks are greater by adding 
Rituximab.17
Anti-TNF-α. Flares of hepatitis have been 
described during treatment with anti-TNF-α 
agents in chronic HBV patients with rheumatoid 
arthritis. Severe flares have also been described 
in association with methotrexate, particularly 
following its withdrawal.18
Bone Marrow Transplantation. Patient with 
HBsAg (+) who undergo allogenic bone marrow 
transplant is in highly immunosuppresive 
condition and has higher risk of HBV reactivation 
(14%-50%). Known risk factors are steroid used, 
anti-HBs (-) donor, and graft-versus-host disease.1 
In graft-versus-host disease, high dose steroid or 
antithymocyte globulin (ATG) are needed which 
suppress the immune system.19 Immunization of 
HBV is recommended for donor and recipient 
who has never been infected by HBV.20
Renal Transplantation. There has been a report 
about declining of renal graft function in patient 
receiving adefovir. Entecavir is drug of choice in 
patient urdergoing renal transplant.
DIAGNOSIS
Currently, no uniform diagnostic criteria are 
available for HBV reactivation. HBV reactivation 
can be confirmed by an increase in serum HBV-
DNA level to more than 1 log higher than that 
of the baseline, an absolute increase exceeding 
6 log10 copies/mL, or serum HBV-DNA turning 
from negative to positive. Serologic evidence 
of chronic HBV infection would be useful. 
Commonly, elevation of HBV-DNA happens 
prior to elevation of transaminase. As reactivation 
may be transient, more frequent HBV-DNA and 
ALT monitoring will lead to a higher rate of 
diagnosis.10
TREATMENT
When a clinical diagnosis is made, 
chemotherapy and potential hepatotoxic agent 
must be ceased and treatment is based on antiviral 
and supportive care.1 Lamivudine, a nucleoside 
analog, is an effective treatment of chronic HBV 
infection. The drug is active in controlling viral 
replication and is therefore potentially useful 
for the treatment of HBV reactivation. Good 
prognosis can be estimated if lamivudine is given 
at the time of  HBV-DNA elevation.21 There is 
a report about the successful of emergency liver 
transplantation in heterologous bone marrow 
transplantation patient with fulminant HBV 
reactivation.22
Figure 3. Dynamics of viral load and transaminase in HBV 
reactivation1
PROGNOSIS
HBV reactivation is related to long-term 
declining of liver function. Eventhough some 
patients can have spontaneous recovery, mortality 
rate occurs in about 5% - 40%. Patient with anti-
HBc (+) has lower risk of reactivation compared 
to patient with HBsAg (+), but mortality rate is 
higher in patient with anti-HBc (+). Mortality 
rate is still high alhough already been treated with 
antiviral because usually the viral load is already 
high and massive immune-mediated hepatocytes 
injury has already occured.23
PROPHYLACTIC
All chemotherapy and immunosuppressive 
candidates should be screened for HBsAg and 
anti-HBc before receiving the treatment.1 There 
are currently two approaches in management 
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of patients at risk, namely treatment of HBV 
reactivation when it is diagnosed, and prevention 
through preempative treatment prior to or 
upon initiation of chemotherapy.6 Preempative 
antiviral therapy was the best approach to prevent 
the reactivation.11
American Association for the Study of Liver 
Diseases (AASLD) 2009 consensus recommend 
prophylactic antiviral therapy for HBV carriers 
at the onset of chemotherapy or of a finite course 
of immunosuppressive therapy.24
European Association for the Study of the 
Liver (EASL) 2009 consensus also recommend 
about HBV vaccination in seronegative patient 
and evaluate HBV-DNA level before starting 
chemotherapy and receiving preempative therapy 
along and continue to at least 12 months after 
chemotherapy.25
Asia Pacific Association for The Study of 
the Liver (APASL) 2008 consensus recommend 
lamivudine as preempative therapy for 
chemotherapy candidates, starting 1 week 
prior to and continue to at least 12 week after 
chemotherapy.26
Perhimpunan Peneliti Hepatologi Indonesia 
(PPHI) 2006 consensus also recommend 
lamivudine therapy before administer 
chemotherapy or immunosuppresive agent 
and should be continue at least 6 weeks after 
treatment.27
Metaanalysis study by Ziakas et al. reveales 
that in 9 trials, cumulative prevalence for 
HBV reactivation in prophylaxis group was 
8.6% compared to 50.6% in control group. 
The incidence for those who did not receive 
prophylaxis therapy are 54.5%-100%.28
For patient receiving monoclonal antibody 
treatment, antiviral therapy should be given 
for at least 12 months because of slow immune 
recovery.29
HBV reactivation can be happened in those 
who already received lamivudine, this maybe due 
to drug resistency because of YMDD (tirosin-
metionin-aspartat) mutant.30 Others nucleoside 
analog like adefovir, entecavir, telbivudine, and 
tenofovir, can be given to those with lamivudine-
resistant.31
CONCLUSION
HBV reactivation is a common complication 
in patient receiving chemotherapy and 
immunosuppressive agent, therefore we should 
be aware regarding its serious implication. Patient 
Figure 4. Screening algorithm and prophylaxis of HBV reactivation1
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with malignancy in HBV endemic area should be 
screened routinely for hepatitis B status before 
receiving cytotoxic chemotherapy. Preempative 
therapy with nucleoside analog had significantly 
reduced the incidence, morbidity, and mortality 
of HBV reactivation.
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